Author Archives: admin


Damaged bone or cartilage? Now, grow your own cells in a lab – Hindustan Times

When 14-year-old Aarav Gulati (name changed on request) met with an accident a couple of years ago while playing football, he injured his knee. A portion of the cartilage was damaged, and doctors used turned to a radical new procedure for a solution. They took Gulatis own cells, grew them in a lab and used them to replace the cartilage and repair the damage in a natural way.

He was an ideal case for the use of regenerative cell therapy that was a fairly new phenomenon in orthopaedic treatment in India, says Dr Yash Gulati, senior joint replacement and spine surgeon, New Delhis Indraprastha Apollo Hospital.

The regenerative cell therapy got US FDA approval this year, and the Apollo group partnered with RMS REGROW, a company that specialises in cell therapy technology, to exclusively offer the treatment to patients in India.

Instead of using artificial implants, the technique helps in healing the bone or cartilage damage in a natural way using a persons own cells to regain normal function. Cultured cells (grown in a lab) are injected into a patient to replace diseased or dysfunctional cells.

Instead of using artificial implants, the technique helps in healing the bone or cartilage damage in a natural way using a persons own cells to regain normal function. Cultured cells (grown in a lab) are injected into a patient to replace diseased or dysfunctional cells. (Illustration: Siddhant Jumde)

A small part of the joint cartilage is taken through a keyhole procedure, and is grown in a special manner to convert it into stem cells in the laboratory, says Dr Gulati. This is then applied on the area showing loss of joint cartilage.

Dr Gulati has so far treated 10 people using this therapy in Apollo, Delhi.

Stem cells lead to growth of joint cartilage in defective areas, and normal new cartilage re-grows. In bone damage, bone marrow cells are harvested, cultured and implanted in the area to be able to re-grow in a healthy way, Dr Gulati says.

In Mumbai, those in need of joint replacement because of injury, wear and tear or other lifestyle and ageing, are also realising that new cartilage can be grown in a lab from ones own cells and used instead of artificial materials.

Chondron or cartilage cell therapy is a patient-specific regenerative medical treatment which naturally regrows original cartilage. The therapy is used for repairing articular cartilage of the knee, ankle and shoulder joints and to help replace missing areas of cartilage.

This is a process where a biopsy of cartilage cells (chondrocytes) is taken from the patients knee, ankle or shoulder, says Satyen Sanghavi, chief scientific officer of Regenerative Medical Services Regrow, a biotechnology company in Mumbai.

Causes of bone or cartilage damage

They are then cultured to grow and multiply in a lab for 3-4 weeks into a surplus population of several million. The cultured cells are then re-implanted in the damaged area in a minimally invasive surgical procedure.

The process comes from eight years of work in cell and tissue therapy research. Chondron ACI is the countrys first cell therapy product.

These cells grow and repair tissue with properties similar to that of normal cartilage present in other joints, says Sanghavi. But replacement alone doesnt solve problems. Patients are expected to follow a rehabilitation program, to help the body adjust to new cells and them get back to day-to-day physical.

Its easy to see the advantages of a process like this. Experts say it may avoid the need for future prosthetic joints replacement (especially partial joint replacement) and allows patients the freedom to continue physical activities as before.

It also poses less risk of disease transmission or infection since it comes from the patients own tissue (no foreign material or metal goes inside the body). It may also halt further progression to osteoarthritis, a common problem with those in need of joint replacement.

The procedure costs Rs.3 to 3.5 lakhs.

In India, more than 500 patients have been treated with both bone and cartilage cell therapy procedures, says Sanghavi.

There is a success rate of more than 95%. During our clinical trials and research, we have treated working professionals, housewives, athletes, army men and mountaineers. Almost all of them have successfully recovered and got back to their active life.

However, this new technique has a flip side, too.

The price could be a bit steep for some because stem cell treatment is expensive; and the treatment gets prolonged as a patient has to wait for some time as cell culture takes time and one cannot bear weight on the affected area while the healing is on. Also, not all patients are suitable for it because it can correct only if damage isnt extensive, says Dr Ankit Goyal, associate professor, Safdarjung Sports Injury Centre (SIC) in Delhi.

Safdarjung Hospital had also treated about 35 patients, who had damaged their cartilage, with the technique a few years ago.

We would send cartilage for culture but only in cases where damage was limited. This is definitely not a substitute for knee or hip replacement procedure where the entire joint is extensively damaged. However, it may prevent the need for replacement later on in life, especially in young patients, he says.

More:
Damaged bone or cartilage? Now, grow your own cells in a lab - Hindustan Times

Is stem cell therapy approved in Singapore? – The Straits Times

Reader Charles Wang wrote to ask if stem cell therapy - the use of stem cells to treat various medical conditions - is approved in Singapore. Mr Wang also asked where one could seek this treatment if it is available. Health reporter Linette Lai answered.

Any new treatment must be backed up by sufficient scientific evidence to ensure that it is safe and effective. However, there is still not enough scientific evidence available for stem cell therapy to be approved as a mainstream treatment in Singapore.

A Ministry of Health spokesman said: "To date, stem cell therapy has not been substantiated by sufficient clinical evidence as a form of mainstream treatment for any diseases or ailments, and it is not available as a treatment in our public hospitals.

"If any registered medical practitioners or institutions want to administer stem cells as a form of medical treatment, it would have to be conducted within the context of clinical trials."

Continue reading here:
Is stem cell therapy approved in Singapore? - The Straits Times

Anger as Scots patients miss out on ‘breakthrough’ stem cell therapy … – Herald Scotland

LUCY Clarke was facing a downhill spiral when she flew to Russia to undergo a cutting edge stem cell transplant.

Two years on she says the procedure not only halted her illness in its tracks, but reversed much of the damage inflicted by multiple sclerosis.

The 41-year-old from Inverness is now backing crowdfunding efforts so that her friend and neighbour, Rona Tynan, can receive the same life-changing operation in Mexico before she becomes too ill to qualify.

Mrs Tynan, 50, has until the end of August to raise the 60,000 needed.

However, both are angry at a cross-border divide which means that a small number of MS patients in England can undergo the treatment for free on the NHS, while in Scotland despite having some of the highest rates of MS in the world the health service has refused patients' funding and no clinical trials are planned.

Mrs Clarke, a chemistry graduate and acupuncturist, began investigating AHSCT (autologous haematopoietic stem cell transplantation) in 2014 after her condition progressed from relapsing-remitting to secondary progressive MS. At the time her son was three and she feared ending up in a wheelchair.

Although the treatment has been available overseas for decades, it has never been routinely available on the NHS and is considered unproven by many neurologists.

It is also a highly aggressive therapy, using intensive chemotherapy to strip out sufferers faulty immune systems before replenishing it with stem cells harvested from their own bone marrow or donor tissue. Despite the risks, many patients including Mrs Clarke credit it with transforming their lives.

She underwent the procedure in Moscow over a period of four weeks in April and May 2015. She said: From when my son was three to when I had the transplant, my walking had deteriorated, I needed to use a walking stick all the time, I had very poor balance, debilitating fatigue, I had brain fog, I used to slur my words.

"Im left-handed and my left hand was really weak so my writing was bad. Other things would come and go numbness in my legs, tingling, cramps in my calves, sore and painful legs. The majority of them have gone since the transplant.

I noticed quite quick improvements in things like balance. The biggest thing is not really having fatigue, and the brain fog completely went. I stopped slurring my words quite quickly after treatment. I was more alert. I had more concentration, more focus. Within six months the shaking in my left arm had gone. Ive still got drop foot in my right leg and I still use a walking stick, but once youve got to the stage of secondary progressive it all gets a bit scary. Things are going downhill and youre told theres nothing that can be done, so really my goal from treatment was just to halt the progression to know I wasnt getting any worse. Thankfully, and luckily, I have seen lots of benefits.

Eighteen months on, MRI brain scans show no signs of disease progression and while Mrs Clarke stresses that the treatment is neither a magic bullet nor a walk in the park, she is supporting Rona Tynans bid to undergo the same surgery in October.

Mrs Tynan, a retired Metropolitan police sergeant and mother-of-two from Inverness, also has secondary progressive MS. She is already in a wheelchair and fears that unless she undergoes the treatment soon she will become too ill. She said: Im a 7.5 out of 10 on the disease progression scale, where 10 is death. Most clinics stop taking you at seven, but Mexico just raised it to 8.5. Thats brilliant for people like myself, but I cant afford to get any more ill.

So far, Mrs Tynans fundraising page on JustGiving has raised nearly 4000, but she is frustrated that more is not being done to help Scottish patients. In England, clinical trials are ongoing in London and Sheffield but a small number of patients with relapsing-remitting MS can be referred for the treatment off-trial, for free, on the NHS. In Scotland, however, eligible patients have been turned down for NHS funding.

Mrs Tynan said: It seems crazy to me that Brits are going to Chicago and Mexico and Russia for a treatment that in the long-run could save the NHS loads of money. Scotland is one of the worst places in the world for MS yet in England you can get this treatment for free. Why arent we fighting in Scotland to get this?

Mrs Clarke added: Its very unfair. It just seems a no brainer to me why they wouldnt make it available not for all patients but for some. The Scottish Government said referral decisions were "for clinicians".

A spokesman said: "Whilst the vast majority of healthcare provided by NHS Scotland is delivered in Scotland, NHS boards can commission treatment in other countries on an ad hoc basis, particularly where highly specialised treatment is involved. Decisions to refer patients are for clinicians, based on agreed guidelines, which ensure best practice, equity of access and consistency of treatment for all patients.

"HSCT is not currently widely available anywhere on the NHS, but people from Scotland can participate in trials held in other centres across the UK, where clinically determined appropriate and beneficial."

Read the rest here:
Anger as Scots patients miss out on 'breakthrough' stem cell therapy ... - Herald Scotland

Siberian scientists say stem cells can treat varicose veins – Russia Beyond the Headlines

Scientists at the Institute of Chemical Biology and Fundamental Medicine (ICBFM) based in Siberia have discovered that stem cells can restore blood flow in veins with clots.

Facebook

Pinterest

WhatsApp

"Quite a lot of pathologies regarding veins still remain unstudied." Source: Getty Images

To help treat varicose veins, scientists need to accelerate the growth of blood vessels, which would be a crucial development for cardiac medicine. A heart attack is caused by damaged arteries, and an ischemic stroke also often results from vascular damage.

"Quite a lot of pathologies regarding veins still remain unstudied," said Igor Mayborodin, a doctor of medical sciences at the stem cell laboratory at ICBFM. "Weve looked into blood flow restoration in situations when there are blood clots. Now were trying to use stem cells to stimulate the growth of veins and bypass the diseased area."

The discovery by Siberian scientists will make it possible to successfully treat diseases of the veins and resulting complications, for example, varicosis, phlebothrombosis (the formation of a blood clot in the vein that leads to its blockage), and even some types of trophic ulcers and cerebral strokes.

Researchers conducted a number of studies on rats, injecting them with stem cells taken from their relatives. The experiment showed that within a week small vessels had formed in the rodents, and in the third week the replacement of the introduced cells with the rodents' own cells began.

The new blood vessels remained in the body but stem cells that formed walls were gradually replaced by those of the rodents. Thus, scientists showed that stem cells can restore blood flow, bypassing damaged veins. Based on the results, a series of articles will be prepared.

Also, scientists witnessed unexpected side effects. "Some of the stem cells die, and then macrophages are attracted to the site, that is, 'ingester' cells capable of actively engulfing and digesting the remains of dead cells," Mayborodin said. "This is what helps a surgical wound be rid of damaged tissue quicker and heal. This is a good result."

The scientists are continuing their state-funded research, and they have obtained a patent for their work. For the time being, however, they cant check the results in clinical tests because Russian law restricts the use of stem cells on humans.

"Wed like to utilize the obtained data in regards to humans, but this is currently not possible," Mayborodin said. "For now were refining the results of the research on cell therapy and clarifying possible complications. But wed like to test our hypothesis at least on a severe case of varicosis in clinical conditions."

Read more:
Siberian scientists say stem cells can treat varicose veins - Russia Beyond the Headlines

Stemcell Stroke hold the key to changing the face of medicine forever. – Checkbiotech.org (press release)

Stem Cell Testomonials

Billions of dollars are being spent at it very rapid pace over the last 10 years trying to get regulatory approval and or something to patent in order to make profit.

But if you look at Stemcell Stroke logically from a non-medical point of View I think as a consumer logic oftentimes outweighs government oversight

God created stem cells as an agent to build and develop of the human body and it is Americal in itself how the process works so why are we counting on the government to tell us its a potential medical miracle when its already a miracle on its own

Its a proven fact that a child grows in approximately nine months between six and 10 pounds but at birth when the Whartons jelly is pushed into the baby system over the next nine months they will grow 3 to 5 times faster logic would say that those stem cells are doing their job and multiplying at a rapid rate as designed by God

Other scientific proof to validate what God already knows is that the older you get the few were stem cells you have in your body, multiplied by the fact if you take Staten drugs as you age for different things they will actually kill out Stemcell Stroke giving you a smaller stem cell count so why in the world would you extract Stemcell Stroke the 40-year-old body and put them back into you thinking that its going to give you the same results as brand-new stem cells from a newborn?

Another known fact that just makes you think about logic and Houston cells work but as you age your ability to heal a cut is slower than when youre young When youre young and get a cut you heal very quickly but if youre 60 or 70 or 80 you heal slower and that is a process that happens because of the workers themselves in your body making you think logically the older you get the few were Stemcell Stroke have thats why it takes longer for a cut to heal.

So being a logical person those things very much intrigued me but I still had questions before I had some foreign object injected into my body so I started asking around and that is when I really became a believer.

I spoke to her mother who had a teenage son injured in a lacrosse accident and was desperate for pain relief She had an MRI done showing a tear in vertebrae and post Stemcell Stroke shins the MRI showed that there was healing just within 30 days and the childs pain was gone.

I spoke to an older gentleman who had stem cells injected through an IV and he said within 60 days he noticed a change in mobility as well as facial changes that were a positive after having a stroke He had done Rehab on his arm and leg and was not happy with the results and after 60 days post stem cell he was 50% better than before and believes its only going to get better over time. His provider said at six months he may want to take another round if he does not get the full effect that hes looking for, but he is very happy already

Doing my research I found a provider who has been doing stem cell injections on his daughter who has down syndrome and not only has he noticed a difference but the private school that she goes to called him out of the blue one day letting him know that his daughter is doing cognitively better. This was 8 on warranted call but they thought the change was so significant that they should notify or at least have a conversation with the family

A lady I I go to church with told me with some embarrassment that she had stem cell injections, but when she found out I was investigating them she was more than happy to tell me her success story

She plays tennis through high school and college and as she aged she started having pain in her knee and buy Christmas of last year she had to stop playing tennis completely and it was very sad and desperate to get back on the court so she got a stem cell injection in both of her knees and after six weeks she was back to playing tennis or the five hours a week. That was over a year ago and shes been actually playing better than she has in her 40s and 30s thanks to Stemcell injections in her knee.

During my research process, I actually met a gentleman who could not even hold a cuppa coffee in his hand and could barely open his hands because of osteoarthritis wanting to know how it worked out I asked him if it was OK if I followed up with him in 60 days At the 3 to 4 weeks. He actually called me to let me know that hes now able to actually not only hold a coffee cup but you can actually right and sign his name but she has not been able to do for years.

The process was actually quite simple, after meeting with my provider and choosing a 1 mL injection going into the office, filling out the paperwork was probably the longest part of the process once in the procedure room it took less than five minutes and I really back did you work within just a couple hours.

I actually noticed a difference within about three days, and my original pain and inflammation I believe went down as well

A surprise happened I actually also had a pain in my left shoulder but it was not worth spending the money on getting an injection for however, I do believe that the stem cells have traveled across my body to my shoulder and have actually made a difference there as well

Another surprise is I believe, and Im not sure how to test but I do feel like I am able to remember and have maybe more mental clarity for lack of better words not sure the medical words or terms but its crazy what the stem cells have the ability to help

Im not a doctor, nor our stem cells the magic bullet but I believe after my experience that there may be some logic to having injections maybe once a year or every other year to help my body do what God designed it to do.

Overall as a consumer the risks at this point were away outweighed by the reward and success of my stem cell injection and I would just advise anybody to think about the government approval and the FDA process and what its going to take for them to approve something thats not a drug, which is completely natural And wait for them to say yes youre able to do this to your body Illogic person such as myself may believe that I have the choice and I am willing to take the risk to make myself or my life better and that should not be regulated by the government and give Stemcell Injections a try

I do believe you are the captain of your body, and you should choose how youre going to take care of it and not count on only doctors and the government to tell you how to make yourself well again so use your logic and make the choice right for you

Read more from the original source:
Stemcell Stroke hold the key to changing the face of medicine forever. - Checkbiotech.org (press release)

NBA Star John Salley Partners with Stem Cell Centers of Excellence … – Market Exclusive

WEST PALM BEACH, FL / ACCESSWIRE / June 29, 2017 / Steve Nudelberg, Principal Thinker of On the Ball Ventures, is pleased to announce the partnership between John Salley and Stem Cell Centers of Excellence.

On June 24, 2017, John Salley had his first stem cell procedure to harvest his own stem cells and create relief in his shoulders and knees. On the Ball, in keeping with our mantra to create ideas and opportunities to grow business, felt that John Salley would be a natural addition to enhance the national roll out of Stem Cell Centers of Excellence treatment clinics. As a spokesperson for the vegan lifestyle and long-time friend of On the Ball, John has a keen understanding of how the body functions and how stem cell treatment is a natural alternative for the athlete community. John is a perfect conduit, says Steve Nudelberg

John Salley, Entrepreneur, NBA Star, Actor, Philanthropist, and Vegan, has suffered years of agonizing pain after a lucrative career in the NBA. He was set to have surgery on his knees and shoulders but, in keeping with his vegan, clean philosophy, Salley partnered with Stem Cell Centers of Excellence to advocate for using your own bodys stem cells to heal itself. I am excited to be part of the future with the team at Stem Cell Centers of Excellence. Two things jump to mind after my recent treatment: one, I cant wait for my body to start healing itself and, two, I feel secure in knowing that my stem cells, which are not getting any younger, are now stored and will be ready should I need them for future use at any time, says John Salley.

Superstar athlete and wellness expert John Salley is the ideal individual to represent Stem Cell Centers of Excellence as we continue educating the public about the benefits of stem cells and the bodys ability to heal itself, said Mike Tomas, President and CEO of U.S. Stem Cell Inc. John has seen first-hand how injuries to athletes, and sports enthusiasts alike, can be devastating with long recovery times. Cutting-edge stem cell treatments for individuals with orthopedic as well as neurological conditions are an excellent option for these patients to improve their quality of life.

With a new clinic in Miami, FL and additional clinics opening soon around the country, Stem Cell COE provides comprehensive stem cell treatments using the U.S. Stem Cell Inc. (OTCQB: USRM) innovative technologies and the latest USSC regenerative medicine research. After treatment, the bodys own healing potential may naturally repair and regenerate damaged tissue. U.S. Stem Cells team of scientists have pioneered in-clinic regenerative medicine protocols and helped thousands of patients to naturally heal. The company is at the forefront of this innovative technology and will continue to create unique solutions for patients in need. For more information or to make an appointment, visit http://www.stemcellcoe.com.

On the Ball has been in business for over twenty-two years. Starting out as a sports marketing company to a traditional marketing agency to business development resource. Acclaimed for its strategic thinking and sales-focused abilities, On the Ball specializes in all things sales. By investing time and talent in emerging ideas, the agency can specifically help companies grow.

About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics, and US Stem Cell Clinic), includes the development of proprietary cell therapy products, as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection, and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as may, will, to, plan, expect, believe, anticipate, intend, could, would, estimate, or continue, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our managements beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled Risk Factors in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.

Contact:

Aziel Shea [emailprotected] (561) 596-9402

SOURCE: U.S. Stem Cell, Inc.

See more here:
NBA Star John Salley Partners with Stem Cell Centers of Excellence ... - Market Exclusive

Stem Cells Play a Role in Acute Myeloid Leukemia Relapse – Technology Networks

Leukemia researchers led by Dr. John Dick have traced the origins of relapse in acute myeloid leukemia (AML) to rare therapy-resistant leukemia stem cells that are already present at diagnosis and before chemotherapy begins.

They have also identified two distinct stem-cell like populations from which relapse can arise in different patients in this aggressive cancer that they previously showed starts in blood stem cells in the bone marrow.

The findings provide significant insights into cell types fated to relapse and can help accelerate the quest for new, upfront therapies, says Dr. Dick, a Senior Scientist at Princess Margaret Cancer Centre, University Health Network, and Professor in the Department of Molecular Genetics, University of Toronto. He holds the Canada Research Chair in Stem Cell Biology and is Co-leader of the Acute Leukemia Translational Research Initiative at the Ontario Institute for Cancer Research. This study was primarily undertaken by post-doctoral fellow Dr. Liran Shlush and Scientific Associate Dr. Amanda Mitchell.

"For the first time, we have married together knowledge of stem cell biology and genetics areas that historically have often been operating as separate camps to identify mutations stem cells carry and how they are related to one another in AML," says Dr. Dick, who pioneered the cancer stem cell field by identifying leukemia stem cells in 1994.

A decade ago, he replicated the entire human leukemia disease process by introducing oncogenes into normal human blood cells, transplanting them into xenografts (special immune-deficient mice that accept human grafts) and watching leukemia develop a motherlode discovery that has guided leukemia research ever since.

The researchers set out to solve the mystery of AML relapse by analysing paired patient samples of blood taken at the initial clinic visit and blood taken post-treatment when disease recurred.

"First, we asked what are the similarities and differences between these samples. We carried out detailed genetic studies and used whole genome sequencing to look at every part of the DNA at diagnosis, and every part of the DNA at relapse," says Dr. Dick. "Next, we asked in which cells are genetic changes occurring."

The two-part approach netted a set of mutations seen only at relapse that enabled the team to sift and sort leukemic and normal stem cells using tools developed in the Dick lab a few years ago to zero in on specific cell types fated to relapse.

"This is a story that couldn't have happened five years ago, but with the evolution of deep sequencing, we were able to use the technology at just the right time and harness it with what we've been working on for decades," he says.

Today's findings augment recent research also published in Nature (Dec.7, 2016) detailing the team's development of a "stemness biomarker" a 17-gene signature derived from leukemia stem cells that can predict at diagnosis which AML patients will respond to standard treatment.

Dr. Dick says: "Our new findings add to that knowledge and we hope that we will soon have a new biomarker that will tell whether a patient will respond to standard chemotherapy, and then another to track patients in remission to identify those where treatment failed and the rare leukemia stem cells are coming back.

"These new kinds of biomarkers will lead to new kinds of clinical trials with targeted chemotherapy. Right now, everybody gets one size fits all because in AML we've never had any opportunity to identify patients upfront, only after they relapse. Now we have the first step to identify these patients at the outset and during remission."

The research was funded by the Ontario Institute for Cancer Research, the Cancer Stem Cell Consortium via Genome Canada and the Ontario Genomics Institute, the Canadian Institutes of Health Research, the Canadian Cancer Society, the Terry Fox Foundation, a Canada Research Chair and The Princess Margaret Cancer Foundation.

This article has been republished frommaterialsprovided byUHN. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference:

Shlush, L. I., Mitchell, A., Heisler, L., Abelson, S., Ng, S. W., Trotman-Grant, A., . . . Dick, J. E. (2017). Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature. doi:10.1038/nature22993

Continue reading here:
Stem Cells Play a Role in Acute Myeloid Leukemia Relapse - Technology Networks

Hurray for Gurdon and Yamanaka, Nobel Prize Winners for Pro-life Medicine – Gilmer Mirror

The research studies carried out by John B. Gurdon (Anglo-Saxon) and Shinya Yamanaka (Japanese) were awarded the Nobel Prize in Medicine. These two scientists are considered of being the fathers of cellular reprogramming. They have achieved to create cells that behave identically to embryonic cells, however, without having to destroy human embryos. The Swiss Academy declared that both Gurdon and Yamanaka have revolutionized the current knowledge of how cells and organisms are developed, which has led to the perfection of the absurd methods of diagnosis and therapy.

Jhon Bertrand Gurdon, professor of the Zoology Department of the University of Cambridge, admitted of feeling extremely honored for such a spectacular privilege.

Moreover, Shinya Yamanaka discovered the so called induced pluripotent stem cells (iPS), which have the same proprieties of the embryonic ones and are able to turn into whatever other type of body cell. He asserted that he will continue to conduct research in order to contribute to society and medicine. For him that is a duty.

Yamanaka created four types of genes that supply cells with their pluripotentiality, in other words, the same capacity that embryonic stem cells have. If implanted in differentiated cells, for example of skin, they become pluripotent stem cells. The iPS supply a vast amount of plasticity just as embryonic stem cells do, however, without requiring the extermination or cloning of human embryos, since the initial cells can be obtained from the same patient. In this aspect, these cells have the same status as adult stem cells do, with the advantage of their versatility.

The dilema that has been stirred by the iPS is being resolved due to recent studies carried out by Leisuke Kaji (Universidad de Edimburgo) and Andreas Nagy (Samuel Lunenfeld Research Institute of Mount Sinai Hospital of Toronto).

The created iPS perennially retain their pluripotentiality. There is still the need of research to be conducted concerning the control of the difference between these cells in order for them to create the tissue that is necessary for each case. As Kaji affirms in The Guardian, it is a step towards the practical use of reprogrammed cells in the field of medicine, which could eventually lead to eliminating the need of counting on human embryos as the main source of stem cells.

The Episcopal Subcommittee for the Family and Defense of Life of the Episcopal Conference, beliefs that no Catholic could support practices such as abortion, euthanasia or the production, freezing and/or manipulation of human embryos.

Clement Ferrer

Independent Forum of Opinion

http://indeforum.wordpress.com/

See the article here:
Hurray for Gurdon and Yamanaka, Nobel Prize Winners for Pro-life Medicine - Gilmer Mirror

GEN Roundup: Top Trends in Tissue Engineering – Genetic Engineering & Biotechnology News

References

1. F.T. Moutos et al., Anatomically shaped tissue-engineered cartilage with tunable and inducible anticytokine delivery for biological joint resurfacing, Proc. Natl. Acad. Sci. U.S.A. 113 (31) E4513E4522, doi: 10.1073/pnas.1601639113.

2. B. Zhang et al., Biodegradable scaffold with built-in vasculature for organ-on-a-chip engineering and direct surgical anastomosis, Nat. Materials 15, 669678 (2016), doi:10.1038/nmat4570.

3. S. Shukla et al., Progenitor T-cell differentiation from hematopoietic stem cells using Delta-like-4 and VCAM-1, Nat. Methods 14(5), 531-538 (May 2017),doi: 10.1038/nmeth.4258. Epub Apr 10, 2017.

4. M.M. Pakulska, S. Miersch, and M.S. Shoichet, Designer protein delivery: from natural occurring to engineered affinity controlled release systems, Science 351(6279):aac4750, doi: 10.1126/science.aac4750.

5. M.M. Pakulska, C.H. Tator, and M.S. Shoichet, Local delivery of chondroitinase ABC with or without stromal cell-derived factor 1 promotes functional repair in the injured rat spinal cord, Biomaterials (accepted April 2017).

6. TissueGene, TissueGene to Highlight Invossa, the Worlds First Cell-Mediated Gene Therapy for Degenerative Osteoarthritis, at JP Morgan Healthcare Conference, Press Release,accessed June 12, 2017.

7. O.J.L. Rackham et al., A predictive computational framework for direct reprogramming between human cell types, Nat. Genetics 48, 331335 (2016), doi:10.1038/ng.3487.

8. D.B. Kolesky et al., Three-dimensional bioprinting of thick vascularized tissue, Proc. Natl. Acad. Sci. U.S.A. 113 (12), 31793184, doi: 10.1073/pnas.1521342113.

9. M.M. Laronda et al., A Bioprosthetic Ovary Created Using 3D Printed Microporous Scaffolds Restores Ovarian Function in Sterilized Mice, Nat. Commun. 8, 15261 (May 16, 2017).

10. I. Sagi et al., Derivation and differentiation of haploid human embryonic stem cells, Nature 532, 107111 (April 7, 2016), doi:10.1038/nature17408.

Read more:
GEN Roundup: Top Trends in Tissue Engineering - Genetic Engineering & Biotechnology News

Scientists manipulate ‘signaling’ molecules to control cell migration – Phys.Org

June 30, 2017 Researchers have found a way to tweak cells' movement patterns to resemble those of other cell types. Credit: Tim Phelps/Johns Hopkins University

Johns Hopkins researchers report they have uncovered a mechanism in amoebae that rapidly changes the way cells migrate by resetting their sensitivity to the naturally occurring internal signaling events that drive such movement. The finding, described in a report published online March 28 in Nature Cell Biology, demonstrates that the migratory behavior of cells may be less "hard-wired" than previously thought, the researchers say, and advances the future possibility of finding ways to manipulate and control some deadly forms of cell migration, including cancer metastasis.

"In different tissues inside the body, cells adopt different ways to migrate, based on their genetic profile and environment," says Yuchuan Miao, a graduate student at the Johns Hopkins University School of Medicine and lead author of the study. "This gives them better efficiency to perform specific tasks." For example, white blood cells rhythmically extend small protrusions that allow them to squeeze through blood vessels, whereas skin cells glide, like moving "fans," to close wounds.

On the other hand, Miao notes, uncontrolled cell migration contributes to diseases, including cancer and atherosclerosis, the two leading causes of death in the United States. The migration of tumor cells to distant sites in the body, or metastasis, is what kills most cancer patients, and defective white blood cell migration causes atherosclerosis and inflammatory diseases, such as arthritis, which affects 54 million Americans and costs more than $125 billion annually in medical expenditures and lost earnings.

Because cells migrate in different ways, many drugs already designed to prevent migration work only narrowly and are rarely more than mildly effective, fueling the search for new strategies to control migratory switches and treat migration-related diseases, according to senior author Peter Devreotes, Ph.D., a professor and director of the Department of Cell Biology at the Johns Hopkins University School of Medicine's Institute for Basic Biomedical Research.

"People have thought that cells are typed by the way they look and migrate; our work shows that we can change the cell's migrating mode within minutes," adds Devreotes.

For the new study, Devreotes and his team focused on how chemical signaling molecules activate the motility machinery to generate protrusions, cellular "feet" that are a first step in migration. To do this, they engineered a strain of Dictyostelium discoideum, an amoeba that can move itself around in a manner similar to white blood cells. The engineered amoebae responded to the chemical rapamycin by rapidly moving the enzyme Inp54p to the cell surface, where it disrupted the signaling network. The cells also contained fluorescent proteins, or "markers," that lit up and showed researchers when and where signaling molecules were at work.

Experiments showed that the engineered cells changed their migration behavior within minutes of Inp54p recruitment. Some cells, which the researchers termed "oscillators," first extended protrusions all around the cell margins and then suddenly pulled them back again, moving in short spurts before repeating the cycle. Fluorescent markers showed that these cycles corresponded to alternating periods of total activation and inactivation, in contrast to the small bursts of activity seen in normal cells.

The video will load shortly

Other cells began to glide as "fans," with a broad zone of protrusions marked by persistent signaling activity.

Devreotes describes the signaling behavior at the cell surface as a series of waves of activated signaling molecules that switch on the cellular motility machinery as they spread. In their normal state, cells spontaneously initiated signaling events to form short-lived waves that made small protrusions.

In contrast, oscillators had faster signaling waves that reached the entire cell boundary to generate protrusions before dying out. Fans also showed expanded waves that continually activated the cell front without ever reaching the cell rear, resulting in wide, persistent protrusions.

The scientists say their experiments show that the cell movement changes they saw resulted from lowering the threshold level of signaling activity required to form a wave. That is, cells with a lower threshold are more likely to generate waves and, once initiated, the activation signals spread farther with each step.

Devreotes says the team's experimental results offer what appears to be the first direct evidence that waves of signaling molecules drive migratory behavior. Previously, his laboratory showed a link between signaling and migration, but had not specifically examined waves.

In further experiments, Devreotes and his team found that they could recruit different proteins to shift cell motility, suggesting, he says, that altering threshold is a general cell property that can change behaviorno matter how cells migrate. His team was also able to restore normal motility to fans and oscillators by blocking various signaling activities, suggesting new targets for drugs that could be designed to control migration.

Devreotes cautions that what happens in an amoeba may not have an exact counterpart in a human cell, but studies in his lab suggest that something like the wave-signaling mechanism they uncovered operates in human cells as well.

The bottom line, says Miao, is that "we now know we can change signaling wave behavior to control the types of protrusions cells make. When cells have different protrusions, they have different migratory modes. When we come to understand the essential differences between cells' migratory modes, we should have better ways to control them during disease conditions."

Explore further: How cells communicate to move together as a group

More information: Yuchuan Miao et al. Altering the threshold of an excitable signal transduction network changes cell migratory modes, Nature Cell Biology (2017). DOI: 10.1038/ncb3495

When an individual cell needs to move somewhere, it manages just fine on its own. It extends protrusions from its leading edge and retracts the trailing edge to scoot itself along, without having to worry about what the other ...

Cell migration is important for development and physiology of multicellular organisms. During embryonic development individual cells and cell clusters can move over relatively long distances, and cell migration is also essential ...

When Greek mythology and cell biology meet, you get the protein Callipygian, recently discovered and named by researchers at The Johns Hopkins University for its role in determining which area of a cell becomes the back as ...

(Medical Xpress) -- Discoveries by a Yale-led team of scientists could lead the way for development of new therapies for treating fibrosis and tumor metastasis. The researchers have both uncovered a signaling pathway that ...

Living cells respond to biochemical signals by moving toward those at higher concentration, a process carefully mapped out by biologists over the past several decades. But cells also move in response to mechanical forces, ...

This heart-shaped image shows two mouse skin cancer cells connected to each other with actin, a protein that is part of the cellular skeleton. Researchers use mouse cells like these to tease out the molecular methods that ...

Nature makes the vibrant pigments manufacturers want for foods and cosmetics, but getting them from plants to the products we buy is so difficult that many manufacturers rely on artificial colors. Now, researchers at Rensselaer ...

For centuries evolutionary biologists have been considering a difficult question: why do some animals 'choose' not to have children and instead help others rear their young? Researchers from Royal Holloway, University of ...

(Phys.org)A team of researchers at Purdue University in the U.S. and the University of Amsterdam and Universit catholique de Louvain in the Netherlands has isolated the gene responsible for producing a protein that aids ...

If cellular identity is to be maintained, it is important that actively transcribed chromatin stretches remain in a loose configuration as long as these genes are needed. Marc Bhler and his group have uncovered a novel ...

Johns Hopkins researchers report they have uncovered a mechanism in amoebae that rapidly changes the way cells migrate by resetting their sensitivity to the naturally occurring internal signaling events that drive such movement. ...

Photosynthesis is one of the most complicated and important processesresponsible for kick-starting Earth's food chain. While we have modeled its more-than-100 major steps, scientists are still discovering the purpose of ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See original here:
Scientists manipulate 'signaling' molecules to control cell migration - Phys.Org